Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27781112 | 0.90 | MEN1 (0.63) | MEN1KMT2APOLBROCK2ROCK1 | |
| SCHEMBL12226572 | 0.90 | MEN1 (0.63) | MEN1KMT2APOLBROCK2ROCK1 | |
| SCHEMBL14198862 | 0.90 | MEN1 (0.63) | MEN1KMT2APOLBROCK2ROCK1 | |
| SCHEMBL5700925 | 0.86 | MEN1 (0.60) | MEN1KMT2APOLBROCK2ROCK1 | |
| SCHEMBL5700932 | 0.86 | MEN1 (0.60) | MEN1KMT2APOLBROCK2ROCK1 | |
| SCHEMBL7994713 | 0.84 | MEN1 (0.58) | MEN1KMT2APOLBROCK2ROCK1 | |
| SCHEMBL27887658 | 0.81 | MEN1 (0.55) | MEN1KMT2APOLBGAASMN1; SMN2 | |
| SCHEMBL7876448 | 0.81 | POLB (0.58) | MEN1KMT2APOLBROCK2ROCK1 | |
| SCHEMBL5312465 | 0.80 | MEN1 (0.51) | MEN1KMT2APOLBROCK2ROCK1 | |
| SCHEMBL1139148 | 0.78 | MEN1 (0.53) | MEN1KMT2APOLBROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6046221-A | USEFUL FOR REDUCING LEVELS OF TUMOR NECROSIS FACTOR-ALPHA IN A MAMMAL | CELGENE CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
| US-5801195-A | TUMOR NECROSIS AGENT INHIBITORS FOR COMBATING CACHEXIA, ENDOTOXIC SHOCK AND RETROVIRUS REPLICATION | CELGENE CORPORATION (US) | 1998-09-01 | — | — | US | disclosed |
| US-5736570-A | ADMINISTERING TO REDUCE TUMOR NECROSIS FACTOR (TNFA) LEVELS IN MAMMAL; RETROVIRAL DISEASE TREATMENT/PROPHYLAXIS | CELGENE CORPORATION (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0800505-A1 | NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES | CELGENE CORPORATION (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020915-A1 | NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES | CELGENE CORPORATION (US) | 1996-07-11 | — | — | WO | disclosed |